Shandong First Medical University
Clinical trials sponsored by Shandong First Medical University, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New antibody treatment offers hope for rare blistering skin disease Results expected Jan 2027 (estimated)
-
New injection aims to heal skin ulcers in rare disease
Disease control Recruiting nowThis phase 2 trial tests an injection called SHR-1139 in 10 adults with ulcerative pyoderma gangrenosum, a rare skin condition that causes painful, open sores. The main goal is to see if the drug can completely close the target ulcer within 12 weeks. Researchers will also check f…
Phase 2 • Sponsor: Shandong First Medical University • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New antibody treatment offers hope for rare blistering skin disease
Disease control Recruiting nowThis study tests a new drug called CM336 in 30 adults with moderate to severe autoimmune bullous disease, a condition where the immune system attacks the skin causing painful blisters. The drug targets specific immune cells to reduce this attack. The main goal is to see if the dr…
Phase 2 • Sponsor: Shandong First Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC